Macrovue's Global Asian Healthcare Portfolio

The Asian Healthcare Vue is a high conviction portfolio of positions in ten stocks from across developed and emerging markets, researched and analysed by our investment team.

Macrovue’s Asian Healthcare Portfolio’s Performance*

* Returns as of 31 August 2018. Past performance is not a reliable indicator of future performance. For full performance numbers and methodology, please click here.

Investing in Asian Healthcare

There is rising demand in Asia for sophisticated healthcare products and services—driven by an ageing and increasingly affluent population, as well as the high prevalence of chronic diseases in the region.

Asia is the most populous continent. Its 4.3 billion inhabitants accounts for 60% of the world’s population. The world’s two most populated countries, China and India, together constitute about 37% of the world’s population. The healthcare market in the region (consisting of pharmaceuticals, medical devices and healthcare technology) is expected to grow from US$1.34 trillion in 2012 to US$2.2 trillion by 2018, implying a compounded annual growth rate (CAGR) of 10.5%. This implies strong growth in healthcare spending per capita – 4.8% CAGR across the region.

As some of the emerging economies grow and prosper, they are likely to spend more on their health and wellbeing. Governments around the region are also increasing their healthcare programmes. This presents opportunities for hospitals, healthcare facilities and pharmaceuticals.

Another driver of growth in demand is ageing populations and rising incidence of chronic diseases which continue burden the healthcare system. In Asia, Japan, Korea, Australia and Singapore are the fastest ageing nations. In Singapore alone, one in five residents in Singapore will be over 65 years of age by 2030 and close to two-thirds of the elderly will have at least one chronic disease.

Given the rise of healthcare costs globally, there is an increased acceptance of generic drugs presenting an opportunity to Indian pharmaceutical companies. Being able to produce life-saving drugs at affordable prices and combat diseases like Cancer and AIDS is critical for any country and Indian pharmaceutical companies are geared up to fulfil this unmet need.

Our investment team has selected 10 companies poised to grow from increased expenditure on healthcare across Asian economies. To start investing or to see the stocks, create a free account.


Meet Macrovue's Investment Team

Clay Carter | Head of Investment Committee

Clay has 25+ years experience managing global equity portfolios. Most recently, he was Head of International Investments at Perennial Investment Partners. Previously, Clay managed investment portfolios at QBE, PM Capital, Legal and General Life of Australia, and AMP. He has developed alternative methods to traditional market analysis and portfolio management and regularly appears on CNBC Asia and Bloomberg TV.

Dev Sinha | Chief Investment Officer

Dev is the co-founder of Macrovue and leads the Equity Research and Product Development teams. He started his career as a quantitative analyst at Putnam Investments in Boston before moving to Singapore to join Bank of America Merrill Lynch. Dev has an MBA from The Fuqua School of Business, Duke University and an MS in Financial Engineering from Columbia University.

Dr. Sid Sahgal | COO

Sid brings almost 20 years of experience in finance and technology. He started his career at Honeywell Aerospace as a software engineer before moving to Bank of America Merrill Lynch in New York as a quantitative analyst. Before starting Macrovue, Sid was a lecturer at UNSW while completing his PhD in Finance. He also holds a Masters in Computational Finance from Carnegie Mellon University.